Bioavailability of the tumor necrosis factor alpha/regulated on activation, normal T cell expressed and secreted (RANTES) biosystem inside the gestational sac during the pre-immune stages of embryo development

J Perinat Med. 2023 Apr 18;51(7):891-895. doi: 10.1515/jpm-2022-0542. Print 2023 Sep 26.

Abstract

Objectives: In-vivo studies of the bioavailability of major components of the tumor necrosis factor alpha (TNFα) biosystem inside the gestational sac during embryogenesis have not been reported. We sought to determine the concentration of TNFα, soluble (s) TNFα receptors (sTNFR1, sTNFR2), and RANTES in the primate extraembryonic celomic fluid (ECF).

Methods: A validated timed-pregnant baboon animal model (N: 10) for experimental research in pregnancy was used to collect paired maternal blood and ECF samples in ongoing pregnancies. The concentrations (pg/dL) of TNFα, sTNFR1, sTNFR2, and RANTES were then determined by ELISA immunoassays.

Results: All animals delivered at term healthy newborns. The differential concentration of TNFα, sTNFR1, sTNFR2, and RANTES between the maternal plasma and the ECF could be determined with ratios for TNFα (5.4), sTNFR2 (1.85) and RANTES (3.59) that contrasted with that of sTNFR1 (0.07), which favored the gestational sac compartment. No significant correlations were noted between maternal plasma and ECF TNFR1, sTNFR2 and RANTES. There was a trend for a correlation between TNFα in maternal plasma and ECF (R=0.74; p=0.07).

Conclusions: We report the physiological concentrations of TNFα, sTNFR1, sTNFR2, and RANTES in extraembryonic celomic fluid during embryogenesis in primates.

Keywords: RANTES; TNFα; TNFα-soluble receptors; celocentesis; embryogenesis; extraembryonic celomic fluid; sTNFR1; sTNFR2; tumor necrosis factor alpha.

MeSH terms

  • Biological Availability
  • Chemokine CCL5
  • Female
  • Gestational Sac / metabolism
  • Humans
  • Pregnancy
  • Receptors, Tumor Necrosis Factor, Type II*
  • T-Lymphocytes / metabolism
  • Tumor Necrosis Factor-alpha*

Substances

  • Receptors, Tumor Necrosis Factor, Type II
  • Tumor Necrosis Factor-alpha
  • Chemokine CCL5